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ABSTRACT
Background: Nonallergic rhinitis with eosinophilic syndrome (NARES) is persistent, without atopy, but with 25% nasal
eosinophilia. Hypereosinophilia seems to contribute to nasal mucosa dysfunction.
Objectives: This analytical case-control study aimed at assessing the presence and severity of nonspecific nasal hyperactivity
and at finding out whether eosinophilia may be correlated with the respiratory and mucociliary clearance functions.
Materials: The symptom score was assessed in 38 patients and 15 controls whose nasal smear was also tested for eosinophils
and mucociliary transport (MCT). Nonspecific nasal provocation tests (NSNPT) with histamine were also carried out, and total
nasal resistance (TNR) was determined.
Results: The symptom score of NARES after NSNPT were not significantly different from the control group, and there was
poor or no correlation among the single symptoms and the differences studied for every nasal reactivity class. This correlation
improved when using the composite symptom score. The most severe eosinophilia was observed in high reactivity groups, and
it was correlated with an increase in TNR. MCT worsened as eosinophilia and nasal reactivity increased. Unlike controls, a
significant correlation was observed between the increase in MCT and TNR.
Conclusions: In NARES, nonspecific nasal hyperreactivity is the result of epithelial damage produced by eosinophilic
inflammation, which causes MCT slow down, an increase in TNR, and nasal reactivity classes, with possible impact on
classification, prognosis, and treatment control.
(Allergy Rhinol 6:e94–e100, 2015; doi: 10.2500/ar.2015.6.0125)
NARES, nonallergic rhinitis with eosinophilic syn-drome, is a special form of chronic and persis-
tent inflammatory rhinitis, which occurs in patients
who are nonatopic. It is characterized by sneezing at-
tacks, profuse aqueous rhinorrhea, nose-palate pruri-
tus, nasal obstruction, and, occasionally, loss of the
sense of smell.1 Its acute stages are triggered by various
factors, including, for instance, temperature changes,
intense perfume, and particular climatic conditions.
Nasal cytology shows a predominance of eosinophils.2
Nonatopy is characterized by negative diagnostic al-
lergy tests.3 Patients with NARES show more severe
nasal symptoms compared with other types of allergic
and nonallergic rhinitis, and they risk developing ob-
structive sleep apnea.4 Patients with chronic rhinitis
show a 2–14% occurrence. Usually, it occurs as an
isolated form, but it can be associated with bronchial
hyperreactivity or as intrinsic asthma in 50% of pa-
tients, with no correlation between the increase in eo-
sinophils count in induced sputum, and in nasal secre-
tion5, with aspirin intolerance and nasal polyps.
NARES may be an early sign of aspirin-exacerbated
respiratory disease, characterized by asthma, nasal pol-
yps, and nonsteroidal anti-inflammatory drug intoler-
ance.6 Pathogenetic factors could include chronic, non-
specific release of histamine, and self-perpetuating
eosinophilic infiltration, with nasal smear that shows
more than 25% eosinophils as a diagnostic criterion.2
Nonspecific nasal hyperactivity (NSNH), which is
the correlation between nasal responsiveness to non-
specific nasal provocation tests (NSNPT) and the
response to everyday life stimuli, is typical of aller-
gic and nonallergic rhinitis, and can entail vascular
and glandular activation as well as the activation of
different neuroregulating systems, which thus deter-
mines the type of response to nasal stimulation.7 In
particular, in allergic rhinitis, NSNH requires a cer-
tain degree of inflammation, which is ensured by the
eosinophil cationic protein and by eosinophils at a
later stage of the allergic reaction.8 Hence, NSNH
and the inflammation of the upper airways could be
correlated with each other. This study aimed at de-
termining whether NSNH is present in NARES and
to what extent, whether eosinophilia diagnosed
through nasal cytology is correlated with the respi-
ratory and mucociliary clearance functions, and
whether it is possible to grade NSNH based on the
nasal reactivity classes.9
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MATERIALS AND METHODS
Study Design
Patients with NARES and healthy adult controls
were screened at the Rhinology and Immuno-allergy
Unit of the Sense Organs Department, Otolaryngology
Section of “Umberto I” General Hospital between
March 2010 and June 2013. Six weeks after screening, at
the first checkup, a prick test was performed, the
symptom score was assessed as well as nasal cytology
and mucociliary transport (MCT). A week later, at the
second checkup, an NSNPT with histamine and rhino-
manometric evaluation of the response was carried out,
and the evoked symptom score was recorded. The
study’s protocol was approved by the ethics committee,
and all the people enrolled were asked to sign an in-
formed consent form. All aspects of the study complied
with the provisions of the Declaration of Helsinki.
Subjects Enrolled
Forty patients with NARES (18 men, 22 women; mean
age, 50.7 years) and 15 healthy volunteers (7 men, 8
women; mean age, 39.4 years) were selected and enrolled
in this study. The clinical history of the patients with
NARES showed persistent symptoms, including sneez-
ing, aqueous rhinorrhea, nasal and palatal pruritus, and
nasal congestion that dated back to 2–5 years earlier, with
an on-again-off-again pattern; the controls, instead, had a
negative clinical history. The two groups underwent a
skin-prick test, a radioallergosorbent test (RAST) to detect
specific Immunoglobulin E antibodies to the most com-
mon allergens in the serum, and, if necessary, a specific
nasal provocation test (SNPT) to ascertain the absence of
any atopy. None of them were on any medical treatment
with drugs that may cause nasal hypo- or hyperreactivity
(which included tricyclic antidepressants, antihyperten-
sive drugs such as clonidine and reserpine, decongestants,
etc.) or with nonsteroidal anti-inflammatory drugs. Anti-
allergenic drugs were discontinued for a 7-week period
before the second checkup. Pregnancy and breast-feed-
ing were exclusion criteria, as were concomitant dis-
eases. They all showed an unmistakably negative clin-
ical history of asthma. Rigid fiberoptic nasal endoscopy
(LUT, Denzlingen, Germany) was carried out on all the
patients and did not show any nasal polyps, any nasal
septum deviation, or any other significant alteration.
None of the patients enrolled had infectious rhinitis in
the 2 weeks before the study. Exclusion criteria also
included smoking and exposure to toxic powders or
substances. Sinus radiography, which was performed
as an ordinary diagnostic procedure, excluded any
radiologic and clinical involvement of the paranasal
sinuses. Hence, the patients with NARES were still
sthenic, that is, in a phase with full nasal symptoms,
with frequent “flares,” but showing no anosmia or
sinusitis.
Skin-Prick Test
The allergy status was assessed in the two groups
based on their sensitization to the most common cate-
gories of allergens by means of a skin-prick test. The
test was considered as positive for sensitization when
it revealed a 3 mm-diameter wheal. The allergens
panel (Stallergenes, Milan, Italy) included Dermatopha-
goides pteronyssinus, Parietaria officinalis, Alternaria tenuis,
Aspergillus fumigatus, graminacee mix, dog, cat, com-
posite mix, olea, cypress, and hazel.
Nasal Cytology Test and Staining
For all the patients, nasal smear was collected by scrap-
ing the medial surface of the inferior turbinate. The ma-
terial collected was spread on a glass slide and fixed with
cytologic fixative. The material was then stained with
May-Gru¨nwald-Giemsa stain (C. Erba, Milan, Italy); then
it was mounted, cover slipped, and observed under an
optical microscope (BM100FL, Seben, Berlin, Germany).
The eosinophil count was performed on 10 immersion
microscope fields (1000) and was expressed as a per-
centage over the cell count total. NARES was diagnosed
when there were 25% eosinophils.
Mucociliary Transport
A small amount of Edicol Orange (Edex, Newcastle,
Australia) powder was spread on the anterior section of
the inferior turbinate by means of a swab. Said powder
was anteroposteriorly transported by the cilia of the nasal
epithelium toward the nasopharynx, and the time re-
quired to cover such distance was the mucociliary clear-
ance time. Edicol Orange left reddish traces along the
way, therefore, it was possible to highlight with the stain-
ing agent collected by means of a swab positioned behind
the soft palate. With this technique, the mucociliary clear-
ance time for healthy patients was 15–18 minutes.
NSNPT With Histamine
Endonasal administration of a solution that con-
tained 2.5 mg of histamine phosphate per milliliter
(Sigma Co, St. Louis, MO) was performed in both nasal
cavities of each subject, with a predosed spray in a
volume of 0.1 mL to give a total dose of 0.5 mg.9 This
dose was the minimum provocation histamine quan-
tity that allowed a 100% increase in total nasal resis-
tance (TNR) (expressed as Pa  sec  cm3) and
determined, based on regression coefficients, the
NSNPT response magnitude according to four nasal
reactivity classes, including low (TNR between 0.51
and 1.1 Pa  sec  cm3), medium (TNR between
1.11 and 2.5 Pa  sec  cm3), high (TNR between
2.51 and 4.7 Pa  sec  cm3), and very high (TNR
4.7 Pa  sec  cm3). TNR values were matched
with histamine doses by using the following expo-
nential equation: ln(TNR)  a  bH, in which “a” and
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“b” were generic regression coefficients, TNR was the
nasal resistance response, and “H” was the indepen-
dent variable, that is, the quantity of histamine inhaled
(0.2–0.8 mg). Regression coefficient “b” designed
curves that represented the borders of the areas that
encompassed the nasal reactivity classes.9 Active ante-
rior rhinomanometry using Version 5 of the Jaeger
Master-Scope (Carefusion, Yorba Linda, California)
was performed 5 minutes before and 5 minutes after
the NSNPT with histamine, and TNR was determined
at a 150 Pa based on the following calculation: TNR 
(right NR  left NR)/(right NR  left NR). A hundred
TNR increase was chosen as the basic value because
such an increase cannot be due to the variations of a
normal nasal cycle because other studies showed im-
portant increases already starting from 75–100%, al-
though without a proper standardization9,10 and be-
cause excellent correlation has been observed between
a minimum 100% TNR increase and the SNPT. Such an
increase was the clinical expression of NSNH.
Symptom Score
The following symptom score11 was adopted: 1 point, 3–4
sneezes; 3 points, 5 sneezes; 1 point, anterior rhinor-
rhea; 1 point, posterior rhinorrhea; 1 point, nasal breath-
ing problems; 2 points, one blocked nostril; 3 points, both
blocked nostrils; 1 point, nose pruritus; 1 point, palatal or
ear pruritus; 1 point, conjunctivitis. The overall symptom
score was deemed positive if it was 5.
Statistics
The VassarStats software (Vassar College, New York,
NY) was used to carry out the statistical analysis. De-
pending on the type of data distribution and on the
differences between the two groups, the nonparametric
Mann-Whitney U-test or the parametric Student t-test
was performed. Linear regression analyses were calcu-
lated with a view to determining the existing correla-
tions of all parameters examined, and p  0.05 values
were deemed statistically significant.
RESULTS
Two patients in the NARES group (5% of cases) were
prick test results positive for D. pteronyssinus ()
and P. officinalis (), which also was confirmed by
RAST. Another patient, who showed an uncertain skin
response for the first allergen and was RAST results
negative, underwent the SNPT and had a negative
result after SNPT. The first two patients were excluded
from the study.
The nasal response to NSNPT with histamine in the
two groups, which was measured based on the symp-
tom score, is shown in Fig. 1. The data are expressed as
median values with 75% confidence intervals. The
comparison of data referred to the symptom score
obtained after and before the NSNPT with histamine
has not allowed differentiation of the NARES from the
control groups. Only the symptom of sneezing reached
a reduced statistical significance (p  0.02). In the
NARES, the index of correlation between the score of
single symptoms and the TNR, MCT, and the eosino-
philia for each reactivity nasal class did not reach, or
reached only for some symptoms, low levels of corre-
lation, which, however, improved when using the com-
posite symptom score (r, from 0.75 to 0.87) (Table 1). The
median values with 75% confidence intervals for the na-
sal obstruction symptom score after NSNPT with hista-
mine in the NARES group are shown in Fig. 2. Such
values were compared with those of TNRs and then were
matched with the nasal reactivity classes obtained after
nasal provocation, thus showing that 39% of patient
showed very high reactivity, 37% showed high reactivity,
21% showed medium reactivity, and 3% showed low
reactivity. The differences among the nasal reactivity
classes so obtained were significant, that is, p  0.0001
between strong and consistent reactivity and p  0.002
between consistent and moderate reactivity. As to the
controls, 20% of them showed low reactivity and 80%
did not show any reactivity after NSNPT.
TNR values after NSNPT with histamine in the NA-
RES group are shown in Fig. 3. The pretest average
(SD) values were 0.22  0.03 Pa  sec  cm3 for the
controls and 0.65  0.27 Pa  sec  cm3 for the
NARES group (p  0.0005). The average (SD) values
after NSNPT were 4.28  2.31 Pa  sec  cm3 for the
NARES group, and 0.31 0.15 Pa sec cm3 for the
control group, and a comparison of the two groups
showed significant results (p  0.0005). In fact, after
NSNPT, 20% of the controls showed an increase in
TNR average value (0.57  0.02 Pa  sec  cm3), that
is, low reactivity, whereas 39% of the patients with
NARES were in the very high reactivity class (average,
6.72  1.32 Pa  sec  cm3), 37% showed high
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Figure 1. Congestion, sneezing, rhinorrhea, and pruritus symp-
tom scores for controls and patients with NARES, before and after
NSNPT with histamine. Data are presented as medians with 75%
confidence intervals.
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reactivity (average, 3.40  0.49 Pa  sec  cm3), 21%
showed medium reactivity (average, 1.7  0.44 Pa 
sec  cm3), and 3% showed low reactivity (Table 2).
These percentages of the subjects were similar to those
mentioned above for the nasal obstruction symptom
after NSNPT. In the NARES group, the mean percent-
age of eosinophils in the nasal smear was 45 9%. The
mean eosinophilia values matched with the reactivity
classes were 54  4% for the very high class, 45  2%
for the high class, 32  5% for the medium class, and
25% for the low class (Table 2). The linear regression
analyses of the relationship between the TNR increase
after NSNPT and the eosinophils counted in the nasal
smear of patients of NARES (Fig. 4) showed remark-
able correlation between the two variables (R2  0.82;
p  0.001). Conversely, there were no eosinophils in
the nasal smear of the control group.
The MCT average (SD) values of the NARES group,
expressed in minutes, was higher than that of controls
(30  7 minutes versus 14  2 minutes; p  0.001), and
the related mean values matched with the reactivity
classes. These values were as follows: 37  4 minutes
for the very high class, 27  2 minutes for the high
class, 24  3 minutes for the medium class, and 19
minutes for the low class (Table 2). MCT was related to
the percentage of eosinophils in the nasal smear of the
NARES group (Fig. 5), and linear regression analysis
showed a determination coefficient of the two vari-
ables, of R2  0.71, with p  0.001. MCT and TNR
responses after NSNPT with histamine in the NARES
group (Fig. 6) exhibited a significant linear correlation
(R2 0.89; p 0.001), whereas there was no correlation
for the control group (R2 0.05; p not significant). In
regard to the TNR, MCT and nasal eosinophilia (Table
2) in the NARES group were observed with significant
differences between before and after NSNPT for all
classes of nasal reactivity (p  0.0005) and for the TNR
between NARES and control groups both before and
after NSNPT (p  0.0005). In the end, the correlations
among TNR, MCT, and nasal eosinophilia were strong
or moderate for every reactivity class (Table 1).
DISCUSSION
NARES is described as a chronic eosinophilic self-per-
petuating inflammation with nonspecific histamine re-
lease. It is characterized by increased tryptase in nasal
fluid (which also characterizes allergic rhinitis and vari-
ous forms of nonallergic rhinitis) and eosinophil cationic
protein levels, whereas the fluid’s Immunoglobulin E
level shows no significant increase. The level of eosino-
phils in the nasal smear, instead, is increased12 as well as
the levels of proinflammatory Th2-type cytokines, IL-6
and IL-17 in the nasal fluid, which seem to be a factor of
Table 1 Index of correlation for nasal reactivity class between Eos, MCT, TNR, and CSS in the NARES
group
Nasal Reactivity Classes Eos vs TNR Eos vs MCT TNR vs MCT Eos vs CSS TNR vs CSS MCT vs CSS
Very high 0.66 0.37 0.84 0.29 0.24 0.32
High 0.57 0.39 0.48 0.49 0.19 0.15
Medium 0.91 0.67 0.68 0.69 0.62 0.47
Overall 0.9 0.84 0.94 0.87 0.79 0.75
Eos  nasal eosinophilia; CSS  composite symptom score; MCT  mucociliary transport; TNR  total nasal resistance.
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Figure 2. Reactivity classes for the nasal obstruction symptom in
patients with NARES after NSNPT with histamine. Data are
presented as medians with 75% confidence intervals. The percent-
age of patients observed in each nasal reactivity classes is reported.
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neutrophil cell infiltration and NARES remodelling pro-
cesses.13 Almost all our patients with NARES (95%) did
not have clinical histories positive for allergy and allergic
sensitization to conventional tests. Only two of the pa-
tients (5%) showed sensitization to perennial allergens.
Hence, hypereosinophilia of the nasal mucosa proved to
be a pathognomonic sign for this disease because it can
contribute to its dysfunction.14–16
NSNH evoked by the NSNPT with histamine17,18 was
significantly stronger in patients with NARES than in the
healthy controls. Generally, nonspecific, autonomic stim-
uli have a stronger effect on nonallergic rhinitis and,
hence, on NARES than they have on healthy subjects or
Table 2 Mean (SD) values of TNR before and after NSNPT with histamine, of MCT, and of nasal
eosinophilia in patients with NARES and in the controls
NARES, Mean (SD) Controls, Mean (SD)
Variables Pre-NSNPT Post-NSNPT Pre-NSNPT Post-NSNPT p* p# p§
TNR, Pa  sec  cm3
Overall 0.65  0.27 4.28  2.31 0.22  0.03 0.31  0.15 0.0005 0.0005
Very high 0.91  0.26 6.72  1.32 0.0005 0.0005¶
High 0.78  0.35 3.40  0.49 0.0005 0.0005
Medium 0.63  0.17 1.71  0.44 0.0005 0.0005**
Low 0.29 (1 case) 0.61 (1 case) 0.24  0.05 0.57  0.02
MCT, min
Overall 30  7 14  2 0.0005
Very high 37  4 0.0005¶
High 27  2 0.01
Medium 24  3 0.0005**
Low 19 (1 case)
Eosinophils, %
Overall 45  9 0 0.0005
Very high 54  4 0.0005¶
High 45  2 0.0005
Medium 32  5 0.0005**
Low 25 (1 case)
MCT  mucociliary transport; TNR  total nasal resistance; NSNPT  nonspecific nasal provocation tests; NARES 
nonallergic rhinitis with eosinophilic syndrome.
*Comparisons between before and after NSNPT in the NARES.
#Comparison between NARES and control groups before NSNPT.
§Comparison among nasal reactivity classes.
¶Very high vs high.
High vs medium.
**Very high vs medium.
Figure 4. TNR linear regression after NSNPT with histamine
versus the eosinophil percentages in nasal smear in the NARES
group (R2  0.82; p  0.001).
Figure 5. MCT linear regression versus the eosinophil percentages
in nasal smear in the NARES group (R2  0.72; p  0.001).
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on patients with allergic rhinitis,1 and strengthen NSNH.
Although the nasal response to NSNPT with histamine of
patients with persistent allergic rhinitis seems to be re-
lated to the symptom score that corresponds to the num-
ber of sneezes and to the quantity of nasal secretions,19 in
our study, it was not possible to differentiate the NARES
group from the control group based on the symptoms.
The composite symptom score11 can be considered an
instrument to verify the nasal reactivity in the patients for
the inclusion of a variety of symptoms, which is prefer-
ably measured in a more objective and reproducible way
from the variation of the TNR. Severe nasal congestion
appeared to be the prevailing symptom20 in the very high
and high classes,9 whereas patients who belonged in the
medium and low categories only showed partial obstruc-
tion. Most patients with NARES showed very high and
high hyperreactivity (76%), whereas medium and low
NSNH with no normal reactivity was observed in the
others subjects (24%). All control group patients belonged
to lower nasal reactivity classes; in particular, 20% of
them showed low reactivity and 80% showed normal
reactivity. In the NARES group, there was good corre-
spondence between the nasal obstruction symptom score
and TNR after the histamine challenge test. The patients
with NARES enrolled in our study showed considerable
nasal eosinophilia, in line with the definition of this spe-
cial form of persistent rhinitis, and more or less signifi-
cant forms of nasal eosinophilia are reported in litera-
ture,21–24 but they have never been related to the nasal
reactivity classes obtained afterward. The nasal reactivity
has been classified as very high, high, medium, and low
based on reactivity coefficients.9
In NARES, the highest nasal eosinophilia values were
observed in patients who belonged to the very high and
high reactivity classes, whereas milder eosinophilia was
shown by the subjects included in the lower medium and
low reactivity classes. This statement was further con-
firmed by the linear regression analysis between the TNR
after histamine and eosinophilia variables. As it has al-
ready been pointed out for late allergic reactions16 and for
persistent allergic rhinitis,25 nasal eosinophilia was corre-
lated with nasal obstruction caused by NSNPT with his-
tamine, thus proving that the eosinophilic inflammation
was the cause for nasal hyperreactivity in patients with
NARES and, therefore, in the relating nasal reactivity
classes. Eosinophils are important cells for the physiopa-
thology of many forms of chronic rhinitis, and there is
strong evidence that they play a crucial role in inflamma-
tion and consequential tissue lesions.26 The granules of
the eosinophils contain toxic basic proteins, most of
which are eosinophil cationic proteins. Experimental
studies on the eosinophil function revealed the cytotoxic
effects on the respiratory epithelium.27,28 Of the patients
with NARES enrolled in our study, the mucociliary clear-
ance time showed a progressive and significant increase
as the proportion of eosinophils in the nasal smear in-
creased, which indicated ciliostasis and a possible rela-
tionship with the nasal reactivity classes.
Neural dysfunction can also contribute to NARES
symptoms.29 Nasal hyperreactivity shows itself with a
worsening of the rhinitic symptoms after NSNPT with
histamine, and it has been established that it can be
caused by disequilibrium in the sympathetic or para-
sympathetic nerve system and by the antidromic re-
lease of some neuropeptides that cause neurogenic
inflammation.2,30,31 This hyperreactivity was associ-
ated with an increase in the quantity of eosinophils in
the smear and results in an increment in nasal resis-
tance. The eosinophils have a cytotoxic effect on the
respiratory epithelium by slowing down the clearance
time; in fact, we have observed a significant correlation
between MCT and TNR obtained after NSNPT with
histamine in the NARES group, which was not the case
for the controls, thus confirming their role in altering
the respiratory function and mucociliary clearance.
CONCLUSIONS
NARES is a poorly understood clinical syndrome, with
complex pathophysiogenetic implications,32–35 in which
the absence of atopy and an increase in nasal eosinophilia
was demonstrated. There is a 25% of eosinophils over
the cell total in the nasal smear, and it is pathognomonic
for this disease. Other authors define it as a nasal hyper-
reactivity syndrome without atopy and with20% nasal
eosinophilia.36 Eosinophils contribute to the dysfunction
of the nasal mucosa. In most cases, NARES showed very
high or high NSNH, and the proportion of eosinophils
had strong correlations with the nasal reactivity classes.
Eosinophils play an important role in causing lesions of
the respiratory epithelium, which result in ciliostasis, that
is, slowing down of mucociliary clearance, which is cor-
related with an increase in their proportion in the nasal
smear. Ultimately, in NARES, NSNH is the result of the
inflammation caused by eosinophils that, by damaging
the respiratory epithelium, slow down MCT, cause TNR
Figure 6. TNR linear regression after NSNPT with histamine
versus the MCT of patients with NARES (R2  0.89; p  0.001).
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increase after NSNPT with histamine, and, hence, higher
relating nasal reactivity classes. This could have useful
applications in NARES, including for classification pur-
poses, based on the response intensity; for prognostic
purposes, in that higher reactivity classes have a worse
prognosis; and to control the efficacy of available treat-
ments (antileukotriene drugs, corticosteroid, capsaicin,
etc.) for NSNH1,37–40 by improving the nasal reactivity
classes.
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